

**Signs and symptoms of cervical cancer not to be missed:**

* Unexplained abnormal vaginal bleeding (especially postcoital bleeding)
* Suspicious looking cervix

**When a person of any age presents with symptoms:**

* follow the diagnostic pathway (not the screening pathway) and perform a co-test (HPV test + LBC)

**Ask patients** about if they identify as Aboriginal and/or Torres Strait Islander background

**Create a safe environment** to support the patient with their decision to disclose their status.

This information can also influence **clinical management** of test results, including colposcopy referral in the intermediate risk pathway.

**Informed choice: self- or clinician-**

**collected sample?**

* **Same accuracy** for HPV-PCR testing.
* Most people (>90%) will have HPV not detected and can return for routine screening in 5 years:
* Approx. 2% will have HPV (16/18) detected and will need referral for colposcopy.
* Around 6% will have HPV (not 16/18) detected and LBC is usually required to inform the risk category (refer to Guidelines).
* **Self-collection** – vaginal sample, no speculum needed. If requested, clinician can assist.
	+ If HPV (not 16/18) detected, the person needs to return for LBC, collected by a clinician
* **Clinician-collection** – cervix sample, needs a speculum
	+ If HPV (not 16/18) detected, the lab will perform reflex LBC, so the person doesn’t need to return for a LBC

Cervical screening

quick reference guide

**After treatment for HSIL (CIN2/3)**

* Annual HPV tests (self- or clinician-collected), starting 12 months after treatment.
* People who have 2 consecutive tests with HPV not detected can return to routine screening.

**Identify and support** under and never-screened people (NCSP guidelines section 5.6).

**Create a safe, respectful and inclusive environment.**

**Provide trauma-informed care.**

**Support shared decision-making with accessible information.**

* **Pregnancy:** an ideal opportunity to offer screening if due or overdue. Self-collection is safe in pregnancy (if clinician-collection is preferred, avoid a cytobrush)
* **Immune-deficient:** people with highly immunosuppressive conditions should be screened every 3 years; those at moderately increased risk are well protected with 5-yearly screening.
* **Post-hysterectomy** management and follow-up depends on prior screening history, indication for hysterectomy and histopathology of the cervical specimen.

**Eligible Population:** asymptomatic women and people with a cervix aged 25–74 yrs.

**Screening method:** HPV test (with partial genotyping and LBC triage).

**Sample collection:** self-collect or clinician-collect **supporting informed choice!**

**Frequency:** every 5 years (for self-collection and clinician-collection).

**Manage results:** according to screening flowchart for low, intermediate and higher risk pathways.

**Exit Testing**: people aged 70-74yrs can be discharged if HPV is not detected at their screening test; if HPV (any type) is detected they are referred for colposcopy.

**Ask and record** if the person identifies as **Aboriginal and/or Torres Strait Islander.**

**There is specific guidance for some population groups** (guidelines chapter 7)

National Cervical Screening Program

Test of Cure

Standards of Care

**